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Type 2 DiabeTeS MelliTuS: RiSk evaluaTion 
anD aDvice in unDeRgRaDuaTe STuDenTS in 
aShRafieh, lebanon
F. Fneish
Hochschule Hannover, Hannover, Germany
Background: Type 2 diabetes mellitus (T2DM) is a chronic lifestyle 
disease. It has become evident that T2DM occurs even among the 
younger age groups.1 In Lebanon, T2DM has a major public health 
impact through high disease prevalence, significant downstream 
pathophysiologic effects, and enormous financial liabilities.2
Objectives: The aim of this study was to determine the risk of T2DM 
among undergraduate students from Ashrafieh city by using the vali-
dated Diabetes Risk Score Questionnaire. This study also offered 
T2DM education and awareness to respondents.
Methods: A cross-sectional study was conducted by using a validated 
questionnaire. Of the total 100 students approached, 79 accepted to par-
ticipate in the study. Respondents were interviewed and scored by using 
the Diabetes Risk Score Questionnaire on the basis of 4 parameters: 
age, abdominal obesity, physical activity, and family history of diabetes.
Results: : Of 79 students screened by using the Diabetes Risk Score 
Questionnaire, 39 (49%) were male, and 40 (51%) were female. In 
description, 23 (29%) respondents were not doing any exercise, and 
only 40 (51%) respondents were without abdominal obesity. Overall, 
10%, 44%, and 46% of the respondents were found to be in the high, 
moderate, and low diabetes risk groups, respectively.
Conclusions: According to the International Diabetes Federation, the 
projected prevalence of T2DM among adults in Lebanon for 2020 is 
20.4%. Our study found that only 46% of respondents were in the low-
risk category. Thus, it is essential to enhance awareness among the youth 
regarding T2DM and also of obesity and physical activity, as most of the 
respondents were found to lead a sedentary lifestyle. Therefore, as per 
the study plan at the end of the questionnaire, a booklet on “Diabetes 
Prevention Advice” was provided to all the respondents.
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coMpulSoRy licenSe in The eu—Two SiDeS 
of The SaMe coin
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A compulsory license state-order is limiting the effects of an indus-
trial property right. To obtain a compulsory license, a licensee must 
first have tried unsuccessfully to obtain the property right of a license 
from the owner. Furthermore, this property right has to be in effect 
and in place. The licensee must have the ability and the willingness 
to use the intellectual property right for his own account. Thus, 
a compulsory license cannot be assigned to third parties. If these 
aforementioned conditions are met, there are 2 conditions for grant-
ing a compulsory license: (1) the licensee has a licensing related to 
the dependent property rights, which is an essential advancement of 
the patented technology; or (2) there is a public interest in granting 
a compulsory license, which is much more common in the case of 
pharmaceutical patents. Normally, public interest is defined that a 
medical treatment method or a drug (in the legal sense) should be 
accessible for each person in principle. This accessibility is not been 
given if a treatment method or a drug is only offered subjectively 
too expensive. Rather, a particularly high benefit must be claimed; 
e.g. initial treatment option of common diseases with good pros-
pects of efficacy, e.g. the domestic market is insufficient supplied or 
if the drug or the investigational medicinal product has much less 
side effects so far. Public interest is, in this case not stated, if the 
treatment results can be achieved with other, more or less equiva-
lent, alternatives. For example, the European Union (EU) published 
on May 17, 2006, a Regulation (EC Regulation No. 816/2006) 
on compulsory licensing of patents relating to the manufacture of 
pharmaceutical products for export to countries with public health 
problems. This regulation establishes a procedure for companies 
in the EU wishing to manufacture generic medicines for use in the 
developing world to apply for a compulsory license from a patent 
holder, which allows their manufacture. The legislation is part of 
wider EU action to tackle public health concerns that the world’s 
least developed and developing countries face, in particular access 
to safe, effective, and affordable medicines. This article compares 
arguments of both opponents and proponents of compulsory licens-
ing, which is a legitimate safeguard provided under the EU and in 
the same line as the TRIPS (Agreement on Trade-Related Aspects 
of Intellectual Property Rights by the World Trade Organization) 
to check misuse of monopoly and to deal with situations of public 
health crisis, especially in the Third World.
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Background: The lives of far too many in the world are being 
blighted and cut short by age- and lifestyle-related chronic diseases 
such as heart disease, stroke, cancer, chronic respiratory diseases, and 
diabetes resulting from urbanization, sedentary lifestyles, changing 
diets, and rising obesity levels. 1Even problems of child overweight 
and obesity are increasing worldwide, leading to a growing inci-
dence of type 2 diabetes. India is the second most populated country 
with a population of > 1.2 billion. Along with this, India’s working 
population is also increasing, which will help the Indian economy 
to grow at a much faster rate than the other emerging economies. 
The working population in India is expected to be close to 64% in 
2026. However, with the increase in the young working population 
and change in lifestyle of this young population, there has been an 
increase in lifestyle-related diseases. The current generation, which 
is used to deskbound work, alcohol consumption, and smoking, 
is more prone to such lifestyle-related diseases.2 It is of great con-
cern to observe elevations in the key risk factors that contribute to 
chronic diseases: use of alcohol/tobacco, obesity, and environmental 
